key: cord-0903641-le3ehs0j
authors: Theodorakopoulou, Marieta P; Alexandrou, Maria-Eleni; Boutou, Afroditi K; Ferro, Charles J; Ortiz, Alberto; Sarafidis, Pantelis
title: Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease
date: 2021-12-14
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab272
sha: 0c7e2c2b5995761da7da84f2771cf5f0619ccc68
doc_id: 903641
cord_uid: le3ehs0j

Hypertension and chronic kidney disease (CKD) are among the most common co-morbidities associated with COVID-19 severity and mortality risk. Renin-angiotensin system (RAS) blockers are cornerstones in the treatment of both hypertension and proteinuric CKD. In the early months of the COVID-19 pandemic, a hypothesis emerged suggesting that use of RAS blockers may increase susceptibility for COVID-19 infection and disease severity in these populations. This hypothesis was based on the fact that angiotensin-converting enzyme 2 (ACE2), a counter-regulatory component of the RAS, acts as the receptor for SARS-CoV-2 cell entry. Extrapolations from preliminary animal studies led to speculation that upregulation of ACE2 by RAS-blockers may increase the risk of COVID-19 related adverse outcomes. However, these hypotheses were not supported by emerging evidence from observational and randomized clinical trials in humans, suggesting no such association. Herein, we describe the physiological role of ACE2 as part of RAS, discuss its central role in COVID-19 infection and present original and updated evidence from human studies on the association between RAS-blockade and COVID-19 infection or related outcomes, with a particular focus on hypertension and CKD.

and developed in a global pandemic from the year 2020 [1] . Since then, COVID-19 has been established as a major issue of public health, infecting over 200 million individuals and accounting for more than 4.5 million deaths worldwide, with numbers continuously rising [2] . The risk of severe COVID-19 disease and associated death increases with older age, male sex and the coexistence of various comorbid conditions, including hypertension, diabetes mellitus, cardiovascular disease and, above all, chronic kidney disease (CKD) [3] .

Initial reports from China, Italy and the United States suggested that hypertension was the most frequent comorbidity among hospitalized COVID-19 patients [4, 5] , as well as among severely ill COVID-19 individuals admitted to intensive care units [6] . As a consequence, early in the pandemic, a large number of observational studies associated COVID-19-related deaths to prevalent hypertension [4, 5, 7] . However, the role of hypertension as a risk factor for the adverse COVID-19 probably needs to be better defined, as there are number of factors that could confound a possible relationship between hypertension and severe COVID-19, including age and common comorbidities, i.e. cardiovascular disease, diabetes mellitus and CKD [8] . The high prevalence of hypertension overall, and particularly in the elderly, could explain a large part of the association between hypertension and COVID-19 severity, as older patients seem to be at higher risk for COVID-19 related complications [9] . In a seminal cross-sectional study designed to delineate some of these issues, Iaccarino et al. showed that age and comorbidities such as coronary heart disease, heart failure, CKD and chronic obstructive pulmonary disease were the most important determinants of death among COVID-19 patients, while hypertension and antihypertensive therapy per se were not associated with adverse outcomes in these individuals [3] . Chronic kidney disease was not listed in initial reports as a risk factor for severe  however, within a few months underlying CKD evolved as one of the most common comorbidities conveying an increased risk for SARS-CoV-2 infection and COVID-19-associated mortality [10, 11] . A study from the United States including 5279 COVID-19 patients showed that underlying CKD was associated with hospital admission and disease severity [12] . In another study from the UK, which included data from 17 million electronic health records, CKD was also identified as a risk factor for COVID-19 related mortality [13] . Furthermore, the results from the European Renal Association (ERA) Registry [14] including 4298 patients receiving kidney replacement therapy showed that both dialysis patients (n = 3285) and kidney transplant recipients (n=1013) had significantly higher 28-day mortality risk than propensity-score matched historical controls.

Interestingly, the mortality risk in both end-stage kidney disease (ESKD) groups was higher in patients aged>75 years, while the presence of several comorbidities also affected outcomes, similar to observations in non-CKD populations [3] .

With the onset of the pandemic, some authors suggested that patients with hypertension or cardiovascular disease who were on renin-angiotensin system (RAS) blockers might be at higher risk of severe COVID-19 [15] , based on previous evidence that SARS-CoV and SARS-CoV-2 bind to their target cells through angiotensin-converting enzyme 2 (ACE2) located in the cell membrane [16] . As RAS-blockers are cornerstones in the treatment of several conditions, including hypertension, heart failure and proteinuric CKD, non-evidence-based, widespread and uncontrolled discontinuation of these drugs would have enormous consequences for cardiovascular and kidney health worldwide [17] [18] [19] . A huge number of publications related to this topic appeared and continue to be published. Thus, the present work is an update on the role of ACE2 within RAS physiology, the crucial role of ACE2 in COVID-19 infection and the evidence from observational

and human studies on the association of RAS-blockade and COVID-19 infection, and associated complications in patients with hypertension and CKD.

The RAS is rather the most important endocrine systems, participating in the regulation of numerous physiological systems. Among others, it plays a key role in the control of blood pressure (BP), by regulating vascular tone, and fluid and electrolyte balance [20] . The main components the RAS involved in BP regulation are angiotensin II (Ang II) and angiotensin 1-7 (Ang 1-7) [21] .

Angiotensin II is a potent vasoconstricting agent, that increases renal sodium and water reabsorption through a direct action in proximal tubules and indirectly, through increase of aldosterone secretion, in distal tubules [22] . In addition to these actions, Ang II also has significant oxidative, inflammatory, and fibrotic actions that are involved in cardiorenal remodeling [22] . The above main effects of Ang II take place through binding to the angiotensin II type 1 receptor (AT1R) and subsequent activation of several signal transduction pathways [22] . On the other hand, the Ang 1-7/ACE2 cascade, known as the non-classic RAS, acts as an endogenous counter-regulatory arm to the Ang II/ACE axis. Angiotensin (1-7) activates the Mas receptor to promote vasodilation, and exert antioxidant, anti-inflammatory, and antifibrotic functions [21] . Components of both RAS pathways are co-expressed in the majority of human tissues, having paracrine and autocrine functions independent of their systemic effects; the balance between these axes determines whether or not tissue injury will occur in response to different stimuli [21] .

Angiotensin-converting enzyme (ACE) is a metalloprotease converting the decapeptide Ang I into octapeptide Ang II, the main mediator of the classic RAS [23] . ACE2 is the pivotal enzyme of the non-classic RAS; it is a trans-membranic mono-carboxypeptidase with 806 amino acids that shares about 40% structural identity and 60% sequence similarity with ACE [24] . ACE2 is highly expressed in the heart (endothelial cells, cardiomyocytes, fibroblasts), blood vessels (endothelial

and smooth muscle cells), lungs (bronchial epithelial cells, type-2 pneumocytes, macrophages), kidney (tubular epithelial cells) and the gut (intestinal epithelial cells) and plays an important role in several cardiovascular and immune pathways [21] . Among multiple functions, the most significant role of ACE2 is the conversion of angiotensin (Ang) I to Ang-(1-9) and Ang II to Ang-(1-7), promoting systemic vasodilatory and anti-inflammatory effects [21] (Figure 1 ). Due to structural differences in the binding sites of ACE and ACE2, the pharmacological class of ACE inhibitors do not inhibit the activity of ACE2 [25] .

The potential association between COVID-19 and RAS was hypothesized early in the course of COVID-19 pandemic. ACE-2 acts as the cell membrane receptor for some strains of coronaviruses including SARS-CoV and SARS-CoV-2, mediating the entrance of the virus into the cells by binding the spike (S) protein [26] . Binding of the N-terminal portion of the viral protein unit S1 to a pocket of the ACE2, along with S protein cleavage between the S1 and S2 units by transmembrane-serine-protease 2 (TMPRSS2), facilitates virus entry into cells, viral RNA release and replication, and cell-to-cell transmission [27] .

Previous data from animal studies have shown that RAS-blockers might upregulate tissue activity or ACE2 expression in the heart, lung and kidneys [28] [29] [30] [31] [32] . However, it was also proposed that soluble ACE2 may behave as a decoy receptor for SARS-CoV-2, limiting viral binding to cell membrane ACE2 ( Figure 2 ). Indeed, the combination of soluble ACE2 and remdesivir markedly improved their therapeutic windows against SARS-CoV-2 in in vitro and animal models [33, 34] . To this end, clinical trials of soluble ACE2 for COVID-19 are ongoing (e.g. NCT05065645) although initial phase 2 trials did not meet the primary endpoint (NCT04335136). In this regard, most, if not all clinical studies addressing the impact of RAS blockade on ACE2 studied soluble ACE2 (which may limit SARS-CoV-2 infection) rather that cell membrane ACE2 (that may potentially favor

SARS-CoV-2 infection). They described multiple determinants of soluble ACE2, including both therapeutic agents and underlying conditions. Thus, in some studies, RAS blockade was associated with lower soluble ACE2 [35] while in others there was no association [36, 37] . A final glimpse of complexity of the system and the need for results of actual clinical trials rather than relying on predictions from preclinical models came for the realization that SARS-CoV-2 forms aggregates, through the Spike protein, with soluble ACE2 or soluble ACE2-vasopressin to enter cells via receptor-mediated endocytosis using AT1R or arginine vasopressin receptor 1B (AVPR1B), respectively [38] . Entry using AT1R would be presumably blocked by ARBs ( Figure 2 ).

In any case, given that increased cell membrane ACE2 in response to RAS blockade, as observed in animals, could theoretically increase the chance of virus entry into organs through increase of the potential entry sites [39] , there was initially much concern about the role of RASblockers on ACE2 expression and, hence, susceptibility to COVID-19 infection [40] . On the other hand, some authors have also proposed that ACE inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) could have a beneficial effect in COVID-19 [41] . More specifically, it has been suggested that either by diminishing production of Ang II with the use of an ACEI, or by blocking the Ang II-AT1R binding with the use of an ARB, there could be an enhanced generation of Moreover, as indicated above, they may block virus entry via AT1R [38] .

In contrast to the above hypotheses, observational studies published in mid-2020 demonstrated that the use of RAS-blockers is not associated with higher risk of COVID-19

infection and disease severity, including mortality [44, 45] . In a population-based case-control study in Italy, the use of RAS-blockers was more common among COVID-19 patients than among controls, but was not associated with COVID-19 infection, nor disease severity [44] . Similar observations were also made in another cohort study including 12,594 patients from USA; there was no association between the use of 5 different classes of antihypertensive treatment (ACEIs, ARBs, beta-blockers, calcium-channel blockers, or thiazide diuretics) and an increased likelihood of a positive test for COVID-19, or with increased risk for severe COVID-19 [45] . In addition, in a multicenter cohort study including more than 1.3 million patients with hypertension from USA and Spain showed that there was no association between COVID-19 diagnosis and exposure to ACEI/ARB therapy versus calcium-channel blockers/thiazide therapy (HR 0.98, 95%CI [0.84-1.14]), as well as no significant difference between RAS-blockers and calcium-channel blockers/thiazides for risk of COVID-19 hospitalization, acute respiratory distress syndrome, acute kidney injury, or sepsis across all comparisons [46] . Finally, in a meta-analysis from Baral et al.

including 52 studies with a total of 101,949 COVID-19 patients, treatment with ACEIs or ARBs was not associated with a higher risk of multivariable-adjusted mortality and severe adverse events [47] .

Of note, there are also some studies indicating a protective effect of RAS-blockers in COVID-19 related outcomes; for example, in a large cohort of 1.4 million patients with different diseases (hypertension, heart failure, diabetes mellitus, CKD) in Sweden, the use of RAS-blockers was associated with a significantly lower risk of COVID-19 related hospitalization and death [48] .

A similar association was observed when ARB use was analyzed separately, whereas ACEI use was

not significantly associated with any outcome [48] . The aforementioned meta-analysis from Baral Association class 3-4), were again excluded. The primary endpoint was the maximal Sequential

Organ Failure Assessment (SOFA) score within 30 days and was not significantly different between the 2 arms [54] . Among the secondary endpoints, the area under the SOFA score and mean SOFA score were significantly lower in the discontinuation than in the continuation group, suggesting that discontinuation of RAS-blockers in COVID-19 may lead to a faster and better recovery [54] .

Nonetheless, these observations should be considered again as hypothesis-generating as the primary result of the study was considered to be neutral. Finally, another recently published prospective, blinded, randomized clinical trial in Iran in 64 patients with hypertension (53.1% females; mean age 66.3±9.9 years) showed that the primary outcome (i.e. hospitalization/ICU length of stay) was not different between patients with continuation of RAS blockers or patients in which RAS blockers were substituted with a calcium channel blocker [55] . It has to be noted, that the conclusions of the As of this writing, there are 2 studies that tried to address this issue (Table 2 ). In a parallel-group, Hopefully, these ongoing clinical trials, as well as the future meta-analyses of randomized trials, will elucidate the optimal use of RAS blockers in patients with COVID-19. 

Changes in the respiratory function of COVID-19 survivors during follow-up: A novel respiratory disorder on the rise?

COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

The Science Underlying COVID-19: Implications for the Cardiovascular System

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

The COVID-19 pandemic: consequences for nephrology

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Factors associated with COVID-19-related death using OpenSAFELY

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction

Cardiovascular system: A Recent Update

Classical Renin-Angiotensin system in kidney physiology

Comprehensive Physiology

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors

Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme

Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection

Development of a novel, pan-variant aerosol intervention for COVID-19

Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease

ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System

Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system

Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

Controversies of reninangiotensin system inhibition during the COVID-19 pandemic

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Reninangiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis

Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis

Association between renin-angiotensinaldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis

Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors

ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19

Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

A statement from the International Society of Hypertension on COVID-19 -International Society of Hypertension

Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19